Skip to content
Triangle logo TriangleGet started
← Full study record

NCT01682083 · OUTCOME

Percentage of Participants With Overall Survival (OS) Events

Dabrafenib With Trametinib in the Adjuvant Treatment of High-risk BRAF V600 Mutation-positive Melanoma (COMBI-AD). · Source last updated 2026-04-21

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

Measure
COUNT_OF_PARTICIPANTS
Unit
Participants
Interval / dispersion
Not reported
Time frame
Approximately 10 years

What was measured

Censoring was performed using the date of last known contact for those who were alive at the time of analysis.

Analysis population: Intent-to-Treat (ITT) Population

Groups in this outcome

Dabrafenib and Trametinib Combination Therapy

Subjects received dabrafenib (150 mg twice daily) and trametinib (2 mg once daily) orally for 12 months.

Dabrafenib and Trametinib Placebos

Subjects received matching placebos orally for 12 months

Group identifiers and denominators belong to this outcome only. They may differ in another outcome or in safety reporting.

Analysis denominator · Participants

GroupSource count
Dabrafenib and Trametinib Combination Therapy438
Dabrafenib and Trametinib Placebos432

Reported measurements

Source class 1

Died (event)

Values in Participants · Interval/dispersion: Not reported
GroupValueSpreadLowerUpperComment
Dabrafenib and Trametinib Combination Therapy125Not reportedNot reportedNot reportedNot reported
Dabrafenib and Trametinib Placebos136Not reportedNot reportedNot reportedNot reported

Censored, follow-up ended

Values in Participants · Interval/dispersion: Not reported
GroupValueSpreadLowerUpperComment
Dabrafenib and Trametinib Combination Therapy313Not reportedNot reportedNot reportedNot reported
Dabrafenib and Trametinib Placebos296Not reportedNot reportedNot reportedNot reported

Censored, follow-up ongoing

Values in Participants · Interval/dispersion: Not reported
GroupValueSpreadLowerUpperComment
Dabrafenib and Trametinib Combination Therapy0Not reportedNot reportedNot reportedNot reported
Dabrafenib and Trametinib Placebos0Not reportedNot reportedNot reportedNot reported
Complete source fields
classes
  1. categories
    1. measurements
      1. group Id
        OG000
        value
        125
      2. group Id
        OG001
        value
        136
      title
      Died (event)
    2. measurements
      1. group Id
        OG000
        value
        313
      2. group Id
        OG001
        value
        296
      title
      Censored, follow-up ended
    3. measurements
      1. group Id
        OG000
        value
        0
      2. group Id
        OG001
        value
        0
      title
      Censored, follow-up ongoing
denoms
  1. counts
    1. group Id
      OG000
      value
      438
    2. group Id
      OG001
      value
      432
    units
    Participants
description
Censoring was performed using the date of last known contact for those who were alive at the time of analysis.
groups
  1. description
    Subjects received dabrafenib (150 mg twice daily) and trametinib (2 mg once daily) orally for 12 months.
    id
    OG000
    title
    Dabrafenib and Trametinib Combination Therapy
  2. description
    Subjects received matching placebos orally for 12 months
    id
    OG001
    title
    Dabrafenib and Trametinib Placebos
param Type
COUNT_OF_PARTICIPANTS
population Description
Intent-to-Treat (ITT) Population
reporting Status
POSTED
time Frame
Approximately 10 years
title
Percentage of Participants With Overall Survival (OS) Events
type
SECONDARY
unit Of Measure
Participants

Download exact source JSON → · Snapshot ctgov-results-191f4516d4760045304b24a0

Preserved source evidence · Not medical advice